Table 1.
Patient | Age | Stage | Histology | Dose Level | XRT dose/Tx time (Gy/days) | Concurrent Pemetrexed Dose Received (mg/m2) |
---|---|---|---|---|---|---|
1 TJ | 55 | IIIB | Ad | 1 | 63/45 | 1150 |
2 ST | 72 | IIIB | Sq | 1 | 63/48 | 900 |
3 LM | 64 | IIIA | Ad | 1 | 39.6/33* | 900 |
4 SR | 45 | IIIB | Ad | 1 | 59.4/57 | 1200 |
5 MW | 54 | IV | Ad | 1 | 63/47 | 1200 |
6 SR | 75 | IIIA | Ad | 1 | 63/51 | 900 |
7 PH | 68 | IIIB | NOS | 2/-1 | 63/55 | 1300 |
8 JD | 72 | IIIB | Ad | 2/-1 | 63/51 | 1150 |
9 JB | 78 | IIIB | NOS | 1A | 63/47 | 900 |
10 BS | 61 | IV | NOS | 1A | 63/49 | 1200 |
11 ES | 63 | IV | Ad | 1A | 63/48 | 900 |
12 JB | 83 | IIIA | Sq | 1A | 63/53 | 1200 |
13 EH | 73 | IV | Ad | 1A | 63/54 | 1200 |
14 ML | 74 | IIIA | Ad | 1A | 63/47 | 1200 |
15 CN | 74 | IIIA | Sq | 1A | 63/49 | 1200 |
16 UG | 62 | IIIA | NOS | 1A | 63/48 | 1200 |
*Pt suffered neutropenic fever/sepsis requiring treatment discontinuation.
Histology: Ad = Adenocarcinoma; Sq = Squamous; NOS = Not-otherwise-specified